The antibody radionuclide conjugates market is growing as oncology research increasingly focuses on targeted radiopharmaceutical therapies and precision medicine. The market was valued at USD 5 billion in 2024 and is forecast to rise from USD 5.5 billion in 2025 to USD 15 billion by 2035, at a CAGR of 10.6%.
Read more: Antibody Radionuclide Conjugates Market
3 Views